---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-179048"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2026-04-27T23:59:59+00:00"
generated_at: "2026-05-15T03:54:01.311146+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Mirum's brelovitug meets Phase 2b primary endpoint in chronic HDV; 100% virologic response at 300 mg QW

## Summary
- 100% of patients on 300 mg QW and 75% on 900 mg Q4W achieved virologic response vs 0% control.
- Primary composite endpoint (virologic response + ALT normalization) reached by 45% and 35% vs 0% control (p=0.003, 0.024).
- Brelovitug was well tolerated; no discontinuations, low grade 3+ events, no related serious AEs.
- Full Phase 2b results to be presented at EASL Congress May 27-30, 2026.
- Phase 3 topline data from AZURE-1/4 expected H2 2026; potential U.S. BLA submission in 2027.

## SEC filing metadata
- accession: 0001193125-26-179048
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2026-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000119312526179048/0001193125-26-179048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000119312526179048/d116875d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-179048
- JSON: https://secwatch.observer/filing/0001193125-26-179048.json
- Plain text: https://secwatch.observer/filing/0001193125-26-179048.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.